Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebban

Showing results (391-400 of 459) with videos related to

Pageof 46
Sort By:
Drug Design, Development and Therapy|December 24, 2021
Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1Asma Bourafai-Aziez, Mohammed Benabderrahmane, Hippolyte Paysant, et al.
Applied Health Economics and Health Policy|February 26, 2013
Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM TrialLionel Perrier, Anne Lefranc, David Pérol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 17, 2009
Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA)H Ghesquières, C Ferlay, C Sebban, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Tumor necrosis factor alpha release is a major biological event associated with rituximab treatmentJ Bienvenu, R Chvetzoff, G Salles, et al.
Science Advances|May 29, 2024
A molecular switch controls assembly of bacterial focal adhesionsBouchra Attia, Laetitia My, Jean Philippe Castaing, et al.
Leukemia|January 17, 2003
Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patientsF Maloisel, L Benboubker, M Gardembas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 12, 2012
Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-upP Colombat, N Brousse, G Salles, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2016
Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapseGaëlle Fossard, Céline Ferlay, Emmanuelle Nicolas-Virelizier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2005
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'AdulteP Feugier, A Van Hoof, C Sebban, et al.
Science Advances|June 17, 2021
Table-top extreme ultraviolet second harmonic generationTobias Helk, Emma Berger, Sasawat Jamnuch, et al.
Pageof 46

Showing results (391-400 of 459) with videos related to

Sort By:
Pageof 46
Drug Design, Development and Therapy|December 24, 2021
Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1Asma Bourafai-Aziez, Mohammed Benabderrahmane, Hippolyte Paysant, et al.
Applied Health Economics and Health Policy|February 26, 2013
Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM TrialLionel Perrier, Anne Lefranc, David Pérol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 17, 2009
Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA)H Ghesquières, C Ferlay, C Sebban, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Tumor necrosis factor alpha release is a major biological event associated with rituximab treatmentJ Bienvenu, R Chvetzoff, G Salles, et al.
Science Advances|May 29, 2024
A molecular switch controls assembly of bacterial focal adhesionsBouchra Attia, Laetitia My, Jean Philippe Castaing, et al.
Leukemia|January 17, 2003
Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patientsF Maloisel, L Benboubker, M Gardembas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 12, 2012
Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-upP Colombat, N Brousse, G Salles, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2016
Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapseGaëlle Fossard, Céline Ferlay, Emmanuelle Nicolas-Virelizier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2005
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'AdulteP Feugier, A Van Hoof, C Sebban, et al.
Science Advances|June 17, 2021
Table-top extreme ultraviolet second harmonic generationTobias Helk, Emma Berger, Sasawat Jamnuch, et al.
Pageof 46